Risk of venous thromboembolism amongst initiators of SGLT-2 inhibitors compared to other glucose-lowering agents

被引：0
|
作者：
Gopalakrishnan, Chandrasekar [1 ]
Desai, Rishi J. [1 ]
Kim, Seoyoung C. [1 ]
Patorno, Elisabetta [1 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2020年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
3982
引用
收藏
页码：591 / 592
页数：2
相关论文
共 50 条
  • [1] Risk of Venous Thromboembolism amongst Initiators of SGLT2 Inhibitors Compared with Other Glucose-Lowering Agents
    Gopalakrishnan, Chandrasekar
    Desai, Rishi J.
    Kim, Seoyoung C.
    Patorno, Elisabetta
    DIABETES, 2020, 69
  • [2] Cardiovascular Effects of New Oral Glucose-Lowering Agents DPP-4 and SGLT-2 Inhibitors
    Scheen, Andre J.
    CIRCULATION RESEARCH, 2018, 122 (10) : 1439 - 1459
  • [3] Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs The CVD-REAL 2 Study
    Kosiborod, Mikhail
    Lam, Carolyn S. P.
    Kohsaka, Shun
    Kim, Dae Jung
    Karasik, Avraham
    Shaw, Jonathan
    Tangri, Navdeep
    Goh, Su-Yen
    Thuresson, Marcus
    Chen, Hungta
    Surmont, Filip
    Hammar, Niklas
    Fenici, Peter
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (23) : 2628 - 2639
  • [4] Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors
    Mordi, Ify R.
    Lang, Chim C.
    HEART FAILURE CLINICS, 2022, 18 (04) : 529 - 538
  • [5] SGLT2 inhibitors: not just another glucose-lowering agent
    Hillel Sternlicht
    George L. Bakris
    Nature Reviews Nephrology, 2016, 12 : 128 - 129
  • [6] SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits
    Preda, Alberto
    Montecucco, Fabrizio
    Carbone, Federico
    Camici, Giovanni G.
    Luscher, Thomas F.
    Kraler, Simon
    Liberale, Luca
    CARDIOVASCULAR RESEARCH, 2024, 120 (05) : 443 - 460
  • [7] SGLT2 inhibitors: not just another glucose-lowering agent
    Sternlicht, Hillel
    Bakris, George L.
    NATURE REVIEWS NEPHROLOGY, 2016, 12 (03) : 128 - 129
  • [8] Letter by Tampaki et al Regarding Article, "Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors"
    Tampaki, Ekaterini Christina
    Tampakis, Athanasios
    Gurke, Lorenz
    Pantos, Costas
    CIRCULATION RESEARCH, 2018, 123 (04) : E1 - E2
  • [9] Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China
    Xiao, Xiang
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I2766 - I2769
  • [10] Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China
    Xiao, Xiang
    Ji, Shuming
    Zheng, Tao
    Wang, Tianzhu
    Jiang, Dapeng
    Liu, Fang
    FRONTIERS IN PHARMACOLOGY, 2024, 15
12345